Espicom publishes over 135 reports on companies developing anti-cancer drugs from the largest blue-chip multinational to smaller specialist organisations - and all phases of development from research to launched products.

For each company you can evaluate:
* Summary: At a glance review of agreements, products and R&D pipeline.
* Overview: Background, ownership structure and research techniques they have developed for drug discovery.
* Agreements: Key details of who the company is collaborating with, and on what.
* Product Portfolio: Product monographs, mechanism of action and indications approved and in development.
* R&D Pipeline: Concise summaries of products in research covering status, indication and clinical trials.
* Financials: An analysis of financial performance including P&L, R&D expenditure and funding. In late 2003, Xenova acquired KS Biomedix Holdings plc (KSB), which has since been renamed Xenova Biomedix. Under the terms of the offer made to KSB shareholders, 1.0714 shares in Xenova were issued in exchange for each share held in KSB. An additional contingent deferred consideration of 10 pence per KSB share held will be paid in Xenova shares upon the commercial sale of TransMID in either the US or European markets before 14th August 2011. Based upon a Xenova closing share price of 15.25 pence on 11th September this valued KSB at £17.0 million, including the contingent deferred consideration payable in respect of TransMID of £6.5 million. This acquisition became unconditional in all respects on 12th September 2003 and the planned integration and rationalisation across the two businesses has been completed.